Alexandra Della Pia, PharmD, MBA, BCOP

Adding venetoclax to treatment with ibrutinib improved outcomes in patients with relapsed or refractory MCL in a phase 3 trial.

Receiving fewer cycles of neoadjuvant chemotherapy and undergoing surgery earlier is associated with better survival outcomes in patients with advanced epithelial ovarian cancer, a meta-analysis suggests.

Vitamin D insufficiency may increase the risk of chemotherapy-induced peripheral neuropathy, according to researchers.

Pembrolizumab plus platinum-pemetrexed chemotherapy may be a new treatment option for patients with advanced pleural mesothelioma.

The combination of camrelizumab, apatinib, and HAIC demonstrated “encouraging” results in patients with advanced HCC, according to researchers.

Some oncology lobbying spending has increased in recent years, while other spending has remained stable.

The most common legal barriers cancer patients face are related to health insurance, financial issues, and disability, a new study suggests.

Osimertinib and chemotherapy is more effective than osimertinib alone as first-line treatment for patients with EGFR-mutant, advanced NSCLC, phase 3 data suggest.

Incidence rates of lung cancer subtypes vary across global regions, data suggest.

The cost-sharing burden of high-deductible health plans may delay breast cancer diagnosis, according to researchers.